Moderna (MRNA) Reports Interim Data From Phase 1 Study of mRNA-2752 Triplet Program

Go back to Moderna (MRNA) Reports Interim Data From Phase 1 Study of mRNA-2752 Triplet Program

Moderna (MRNA) Issues Statement on IP

November 11, 2021 1:02 PM EST

Moderna (NASDAQ: MRNA) has recognized the substantial role that the NIAID has played in helping to develop Modernas COVID-19 vaccine by including NIAID scientists as co-inventors on published patent applications where they have made inventive contributions.

Under U.S. patent law, there are strict rules for determining who should be listed as inventors on a patent. Just because someone is an inventor on one patent application relating to our COVID-19... More

Pfizer (PFE) Asks FDA to Amend EUA and Include Booster for Everyone 18+, Analyst Sees Good Chances for Winning Approval and Upgrades BioNTech (BNTX) to Buy

November 11, 2021 9:01 AM EST

Yesterday, Germany recommended only the Covid-19 vaccine developed by Pfizer (NYSE: PFE) and BioNTech (NYSE: BNTX) for under the 30s as it causes fewer heart inflammations in younger people than the Moderna (NASDAQ: MRNA).

The committee also recommended pregnant women receive only the BioNTech/Pfizer vaccine.

In the meantime, two... More